Dx Groups To FDA: Time For Companion Diagnostics Guidance Is Now
This article was originally published in The Gray Sheet
Executive Summary
Industry groups representing test manufacturers, labs, drug firms and others are redoubling their pressure on FDA to clarify the regulatory requirements for co-development of diagnostics and drug treatments
You may also be interested in...
FDA To Address Companion Dx Development In Separate Guidances
FDA hopes to issue draft guidance on companion diagnostics this year, but the document will focus only on the process for adding a diagnostic to an already marketed drug, not simultaneous drug/diagnostic development, according to an agency official.
FDA To Address Companion Dx Development In Separate Guidances
FDA hopes to issue draft guidance on companion diagnostics this year, but the document will focus only on the process for adding a diagnostic to an already marketed drug, not simultaneous drug/diagnostic development, according to an agency official.
FDA Aims For Flexibility In Upcoming Drug/Test Co-Development Guidance
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed